MCS
ACIU icon

Metatron Capital SICAV’s AC Immune ACIU Stock Holding History

Metatron Capital SICAV’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$218K Buy
+44,000
New +$256K 0.21% 106

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Metatron Capital SICAV's ACIU Position: Q4 2021 in Review

Metatron Capital SICAV opened a new position in AC Immune (ACIU) in Q4 2021: 44,000 shares worth $218K. The stake represents 0.21% of the portfolio and ranks #106 among its holdings.

44 funds tracked by Wall St. Rank hold ACIU as of Q4 2021.

  • Metatron Capital SICAV held 44,000 shares of AC Immune worth $218K as of Q4 2021.
  • AC Immune was a new Metatron Capital SICAV position in Q4 2021.
  • AC Immune made up 0.21% of Metatron Capital SICAV's portfolio in Q4 2021, its #106 holding.
  • 44 funds tracked by Wall St. Rank held AC Immune as of Q4 2021.

Based on Metatron Capital SICAV's 13F filing for Q4 2021, filed 15 Feb 2022.